InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

NYSE:NSPR opened at $2.68 on Wednesday. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.80. The business has a 50 day simple moving average of $2.86 and a 200 day simple moving average of $2.76. The firm has a market capitalization of $79.57 million, a P/E ratio of -3.57 and a beta of 0.88.

Hedge Funds Weigh In On InspireMD

Several hedge funds and other institutional investors have recently made changes to their positions in NSPR. Renaissance Technologies LLC bought a new stake in InspireMD during the 4th quarter valued at $27,000. Legato Capital Management LLC acquired a new position in shares of InspireMD during the fourth quarter valued at $47,000. Schonfeld Strategic Advisors LLC increased its holdings in shares of InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares during the period. Northern Trust Corp raised its stake in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after purchasing an additional 24,452 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in InspireMD in the fourth quarter worth about $191,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.